SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.16 CNY | -1.39% |
|
-2.07% | +7.33% |
| Apr. 25 | Sunshine Guojian Pharmaceutical Co., Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Mar. 21 | Sunshine Guojian Pharmaceutical's Profit Surges Sixfold in 2023 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Sunshine Guojian Pharmaceutical Shanghai Co Ltd is a China-based company mainly engaged in the research and development, industrialization and commercialization of antibody drugs. Its products are mainly used to treat major diseases such as autoimmune diseases and tumors. The Companyâs product, recombinant human type II tumor necrosis factor receptor-antibody fusion protein (trade name: YISAIPU), is a fully human antibody drug used to treat rheumatoid arthritis, ankylosing spondylitis and psoriasis. The Company mainly conducts its businesses in Mainland China.
Sector
Pharmaceuticals
Calendar
2024-08-21
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
24.16
CNY
Average target price
32.43
CNY
Spread / Average Target
+34.23%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +7.33% | 2.09B | |
| -1.26% | 89.46B | |
| +2.76% | 40.74B | |
| -9.16% | 33.03B | |
| +55.32% | 24.68B | |
| -16.68% | 15.12B | |
| -9.03% | 12.81B | |
| -12.11% | 11.79B | |
| -43.61% | 11.64B | |
| +7.79% | 8.9B |
- Stock Market
- Equities
- 688336 Stock
- News Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd
- Sunshine Guojian Pharma Gets Nod to Test SSGJ-611 As Pulmonary Disease Treatment
